New Jersey Federal Judge Denies Dismissal Of Lanham Act Dispute Between Drug Makers
TRENTON, N.J. — Allegations that Actavis Inc. falsely marked a generic form of oxymorphone hydrochloride extended-release tablets as therapeutically equivalent (“AB rated”) to an updated and allegedly improved brand name drug...To view the full article, register now.
Already a subscriber? Click here to view full article